Inventor · disambiguated record
Nikolaos Papaioannou
Also filed as: PAPAIOANNOU NIKOLAOS
19 granted patents·9 pending applications·76 citations·filing 2015–2023
93Inventor score
Files withTAKEDA PHARMACEUTICALS CO13PFIZER10SHIRE HUMAN GENETIC THERAPIES3CERTA THERAPEUTICS PTY LTD2
Top patents by PatentIndex Score
28 records- 0197US11702424B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2020·Granted Jul 18, 2023·4 cites·8 claims
- 0295US11370803B2Heteroaryl plasma kallikrein inhibitorsTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Jun 28, 2022·5 cites·17 claims
- 0395US9879022B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2016·Granted Jan 30, 2018·19 cites·22 claims
- 0495US9458168B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2015·Granted Oct 4, 2016·17 cites·44 claims
- 0594US11787796B2Plasma Kallikrein inhibitors and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Oct 17, 2023·4 cites·20 claims
- 0693US11352356B2Inhibitors of plasma kallikrein and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Jun 7, 2022·4 cites·29 claims
- 0792US10730874B2Inhibitors of plasma kallikrein and uses thereofSHIRE HUMAN GENETIC THERAPIES·Filed 2019·Granted Aug 4, 2020·7 cites·18 claims
- 0891US10793579B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2019·Granted Oct 6, 2020·3 cites·8 claims
- 0989US12065448B2Heteroaryl plasma kallikrein inhibitorsTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Aug 20, 2024·1 cites·19 claims
- 1086US10329302B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2018·Granted Jun 25, 2019·3 cites·2 claims
- 1185US12202836B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2023·Granted Jan 21, 2025·0 cites·14 claims
- 1285US10174000B2Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulatorsPFIZER·Filed 2016·Granted Jan 8, 2019·5 cites·10 claims
- 1380US2024199602A1Inhibitors of plasma kallikrein and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 1479US11168083B2Inhibitors of Plasma Kallikrein and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Nov 9, 2021·1 cites·20 claims
- 1579US10316018B2Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulatorsPFIZER·Filed 2018·Granted Jun 11, 2019·2 cites·4 claims
- 1676US11014873B2Anti-fibrotic compoundsCERTA THERAPEUTICS PTY LTD·Filed 2018·Granted May 25, 2021·1 cites·16 claims
- 1773US12221441B2Plasma kallikrein inhibitors and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2023·Granted Feb 11, 2025·0 cites·19 claims
- 1873US11905285B2Inhibitors of plasma kallikrein and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Feb 20, 2024·0 cites·20 claims
- 1971US12441724B2Inhibitors of plasma kallikrein and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Oct 14, 2025·0 cites·29 claims
- 2069US11603349B2Anti-fibrotic compoundsCERTA THERAPEUTICS PTY LTD·Filed 2021·Granted Mar 14, 2023·0 cites·16 claims
- 2159US2024199612A1Imidazopyridinyl inhibitors of plasma kallikreinSHIRE HUMAN GENETIC THERAPIES·Filed 2022·Application pending·0 cites
- 2258US2024199613A1Polycyclic inhibitors of plasma kallikreinTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 2358US2024226106A1Inhibitors of plasma kallikreinSHIRE HUMAN GENETIC THERAPIES·Filed 2022·Application pending·0 cites
- 2454US2024382482A1Plasma kallikrein inhibitorsTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 2554US2024228488A1Heteroaryl inhibitors of plasma kallikreinTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 2652US2023167132A1Forms and compositions of inhibitors of plasma kallikreinTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 2741US2019270778A1Cyclic Peptides As C5a Receptor AntagonistsPFIZER·Filed 2017·Application pending·0 cites
- 2836US2016368919A1Novel pyridine pyrazinones as bet-family bromodomain inhibitorsPFIZER·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nikolaos Papaioannou files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →